Hemoglobin variant, A2 and F quantitation, blood

Alphabetical Test listing

Hemoglobin variant, A2 and F quantitation, blood-994

  
Hemoglobin variant, A2 and F quantitation, blood
  
994
  
LAB994
  
MSO
  
A2F
Hb F level
HBF
S monitoring
SFMON
Sickle monitoring
  

Monitoring patients with sickling disorders who have received hydroxyurea or transfusion therapy

  
EDTA whole blood
  
  
4 mL
  
1.0 mL
  
  1. Submit fresh specimen
  2. Do not transfer blood to other containers
  

Lavender (EDTA), 4mL

  
ACD whole blood
Heparin whole blood
  

Yellow ACD (A or B)

 

Dk green heparin (Li or Na), no gel

 

  

Yellow ACD (A or B)

Dk green heparin (Li or Na), no gel

 

  

Refrigerated (preferred) - 10 days

Ambient - NO

Frozen - NO

  
7 days
  
Mayo Clinic Laboratories (HGBCE): R-NX
  
Mo - Sa 7 am, 1 pm
  
2 days
  

Capillary electrophoresis

  

Hemoglobin A

1 - 30 days: 5.9 - 77.2%

1 - 2 months: 7.9-92.4%

3 - 5 months: 54.7 - 97.1%

6 - 8 months: 80.0 - 98.0%

9 - 12 months: 86.2 - 98.0%

13 - 17 months: 88.8 - 98.0%

18 - 23 months: 90.4 - 98.0%

≥ 24 months: 95.8 - 98.0%

 

Hemoglobin A2

1 - 30 days: 0.0 - 2.1%

1 - 2 months: 0.0 - 2.6%

3 - 5 months: 1.3 - 3.1%

≥ 6 months: 2.0 - 3.3%

 

Hemoglobin F

1 - 30 days: 22.8 - 92.0%

1 - 2 months: 7.6 - 89.8%

3 - 5 months: 1.6 - 42.2%

6 - 8 months: 0.0 - 16.7%

9 - 12 months: 0.0 - 10.5%

13 - 17 months: 0.0 - 7.9%

18 - 23 months: 0.0 - 6.3%

≥ 24 months: 0.0 - 0.9%

  

This test is intended for monitoring purposes, such as the increase in hemoglobin F (Hb F) after therapy, or the levels of hemoglobin variants after transfusion. The HPFH / Hemoglobin F, Red Cell Distribution, Blood test is a flow cytometry assay that determines the distribution of Hb F within red blood cells.

  
83020
  
01/20/2021